|Videos|August 1, 2020
Robert Busch, MD: EMPEROR-Reduced Topline Data and SGLT2 Class
Author(s)Patrick Campbell
A practicing endocrinologist discusses his reaction to topline results from EMPEROR-REDUCED and what he hopes to see in the presentation at ESC 2020.
Advertisement
Hear from Robert Busch, MD, as he offers his thoughts on the topline results of EMPEROR-REDUCED. Released on June 30, topline results of the study indicate use of empagliflozin (Jardiance) was associated with a reduction in the composite endpoint of death and worsening heart failure.
Scheduled to be presented almost one year after the results of DAPA-HF, full results of EMPEROR-REDUCED could definitively prove the benefit seen on heart failure is truly a class effect of SGLT2 inhibitors.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on HCPLive
1
Diabetes Increases Mortality Risk Across All Major Organ Transplants
2
GLP-1 RAs Show Renal, Survival Benefits in Kidney Transplant Recipients With Type 2 Diabetes
3
How to Counsel Patients About Skincare Safety, Sunscreen Safety, and Product Ingredients
4
What Are Some Clinical Pearls in Pediatric Dermatology? With Lisa Swanson, MD
5























































